Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy - NCT00619983-27157(Clinical Trial 203571)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Winston-Salem |
|
State:
|
|
NC |
| Zip Code: |
|
27157 |
| Conditions: |
|
Diabetic Neuropathic Pain - Chronic Low Back Pain |
| Purpose: |
|
The purpose of the study is to determine whether the combination of the the three drugs
gabapentin, duloxetine, and donepezil are effective in treating pain in people with diabetic
neuropathy or patients with failed low back syndrome (chronic back pain).
|
| Study summary: |
|
Neuropathic pain is a complex and likely heterogeneous disorder, and we recognize that
clinically useful agents such as opioids, gabapentin, and antidepressants may be effective
precisely because they have multiple mechanisms of action at multiple sites. This study,
however, will not only provide important mechanistic information regarding one cascade which
can be manipulated for analgesia, but will also provide much needed systematic and practical
guidance for multi-drug therapy in patients with neuropathic pain.
This study in patients with diabetic neuropathic pain and patients with failed low back
syndrome, culminate in a quantitative description of interactions between activators of
descending noradrenergic activity, norepinephrine transporter inhibitors, and cholinesterase
inhibitors to exploit the plasticity of analgesia in chronic pain states. We will focus on
practical applications, using clinically approved drugs, including gabapentin (Neurontin®)
to activate noradrenergic activity, duloxetine (Cymbalta®) to inhibit the norepinephrine
transporter, and donepezil (Aricept®), approved for the treatment of Alzheimer's dementia,
but not previously tested to treat neuropathic pain, to inhibit cholinesterase.
After the baseline measurements and physical examination patients will be trained to use a
Personal Digital Assistant (PDA) to answer questions about their diabetic neuropathic pain
or their chronic back pain. Upon successful completion of these tasks the patients will be
randomized to receive one of the drug choices or placebo (inactive pill).
The study will last for a total of 16 weeks and includes 5 visits to the research center
with each visit lasting approximately 2 hours. |
| Criteria: |
|
Inclusion Criteria:
- Diagnosis of diabetic neuropathy
- Age 18-80
- Willing to temporarily discontinue gabapentin or monoamine reuptake inhibitors upon
entry into the study
Exclusion Criteria:
- Pregnancy
- Allergy to study medications
- Uncontrolled narrow-angle glaucoma
- Currently being treatment with thioridazine (Mellaril)
- Unstable medical conditions including cardiac, pulmonary, renal or hepatic diseases
- Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of randomization |
|
|
|
| Study is available at: |
|
Wake Forest University Baptist Medical Center
Winston-Salem, NC 27157
United States
Primary Contact:
Regina Curry, RN, CCRC
Email: recurry@wfubmc.edu
Phone: 336-716-4294
Secondary Contact:
Regina Curry, RN, CCRC
Email: recurry@wfubmc.edu
Phone: 336-716-4294 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 22, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|